Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)

Market Cap	3.05B
Revenue (ttm)	167.17M
Net Income (ttm)	-137.72M
Shares Out	109.93M
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	859,091
Average Volume	1,114,947
Open	26.76
Previous Close	27.01
Day's Range	26.72 - 27.68
52-Week Range	15.24 - 33.67
Beta	0.83
RSI	64.02
Earnings Date	Apr 24, 2026

About Jiangsu CoWin Biotech

Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and protection, PCR, RT-PCR, and qPCR products, molecular diagnosis, isothermal amplification, nucleic acid mass spectrometry, next generation sequencing, nu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 770
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688426

Financial Performance

In 2024, Jiangsu CoWin Biotech's revenue was 125.88 million, a decrease of -26.54% compared to the previous year's 171.34 million. Losses were -157.21 million, 86.2% more than in 2023.